Cystic kidneys are common causes of end-stage renal disease, both in children and in
adults. Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary
kidney disease and one of the most common causes of end-stage kidney disease. Multiple …

Background In a previous trial involving patients with early autosomal dominant polycystic
kidney disease (ADPKD; estimated creatinine clearance,≥ 60 ml per minute), the …

Data indicate significant phenotypic and genotypic overlap, plus a common pathogenesis,
between two groups of inherited disorders, autosomal dominant polycystic kidney diseases …

Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by the progressive
development of kidney cysts, often resulting in end-stage renal disease (ESRD). This …

In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has
been limited to the management of its symptoms and complications. Recently, the US Food …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark
TEMPO 3: 4 trial—marked a transformation in the management of autosomal dominant …

Disorders of the autosomal dominant polycystic kidney disease (ADPKD) spectrum are
characterized by the development of kidney cysts and progressive kidney function decline …

Abstract Recently, the European Medicines Agency approved the use of the vasopressin V2
receptor antagonist tolvaptan to slow the progression of cyst development and renal …